The global CGM for non-insulin-treated Type 2 diabetes market size was valued at USD 1.4 billion in 2025 and is projected to grow from USD 1.6 billion in 2026 to USD 3.5 billion by 2033, at a CAGR of 10.2% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 73.7% in 2025. The global CGM for non-insulin-treated Type 2 diabetes market is experiencing strong growth, driven by rising prevalence of Type 2 diabetes, growing clinical evidence supporting CGM use among non-insulin-treated patients, expanding guideline recognition, increasing adoption of over-the-counter (OTC) CGM systems, and greater consumer awareness of continuous glucose monitoring insights.
Recent evidence shows that CGM can improve HbA1c and time in range in non-insulin-treated patients, while the 2025 ADA Standards of Care expanded consideration of CGM for adults using non-insulin therapies. The emergence of OTC platforms is also lowering access barriers and broadening CGM beyond traditional prescription-based diabetes management toward lifestyle, nutrition, fitness, and metabolic-health monitoring.
The role of continuous glucose monitoring (CGM) is expanding beyond insulin-treated diabetes, with emerging clinical evidence supporting its use among adults with type 2 diabetes (T2D) who are not using insulin. New findings presented at the American Diabetes Association (ADA) 2026 Scientific Sessions indicate that CGM can significantly improve glycemic control in this population, strengthening the clinical rationale for broader adoption of CGM in primary care.
The CONNECT randomized controlled trial evaluated 283 adults with non-insulin-treated T2D across 22 U.S. primary care practices over 26 weeks. Participants had a mean baseline A1C of 8.8%, with nearly one-third having A1C levels of at least 9%. Patients were randomized to use the Dexcom G7 CGM or receive routine care using standard blood glucose meter testing. The study found that 82% of adults using CGM improved their blood glucose levels, while CGM use produced a 0.9 percentage-point greater reduction in A1C compared with routine care. Participants also spent approximately five additional hours per day within the target glucose range of 70-180 mg/dL.
Recent evidence shows that CGM can improve HbA1c and time in range in non-insulin-treated patients, while the 2025 ADA Standards of Care expanded consideration of CGM for adults using non-insulin therapies. The emergence of OTC platforms is also lowering access barriers and broadening CGM beyond traditional prescription-based diabetes management toward lifestyle, nutrition, fitness, and metabolic-health monitoring.
The role of continuous glucose monitoring (CGM) is expanding beyond insulin-treated diabetes, with emerging clinical evidence supporting its use among adults with type 2 diabetes (T2D) who are not using insulin. New findings presented at the American Diabetes Association (ADA) 2026 Scientific Sessions indicate that CGM can significantly improve glycemic control in this population, strengthening the clinical rationale for broader adoption of CGM in primary care.
The CONNECT randomized controlled trial evaluated 283 adults with non-insulin-treated T2D across 22 U.S. primary care practices over 26 weeks. Participants had a mean baseline A1C of 8.8%, with nearly one-third having A1C levels of at least 9%. Patients were randomized to use the Dexcom G7 CGM or receive routine care using standard blood glucose meter testing. The study found that 82% of adults using CGM improved their blood glucose levels, while CGM use produced a 0.9 percentage-point greater reduction in A1C compared with routine care. Participants also spent approximately five additional hours per day within the target glucose range of 70-180 mg/dL.
Global CGM for Non-Insulin-Treated Type 2 Diabetes Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, the analyst has segmented the global CGM for non-insulin-treated Type 2 diabetes market report based on product, application, connectivity, distribution channel, and region:Product Outlook (Revenue, USD Billion, 2021 - 2033)
- Sensor
- Applicator
- Transmitter
- Device / Reader
Application Outlook (Revenue, USD Billion, 2021 - 2033)
- Glucose / Diabetes Management
- Lifestyle Monitoring
- Diet & Nutrition Monitoring
- Physical Activity & Fitness Monitoring
- Weight Management
Connectivity Outlook (Revenue, USD Billion, 2021 - 2033)
- Bluetooth
- 4G / Cellular
- NFC
Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Pharmacies
- E-commerce
- Others
Region Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Russia
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Thailand
- Singapore
- Malaysia
- Taiwan
- Vietnam
- Philippines
- Latin America
- Brazil
- Argentina
- MEA
- Saudi Arabia
- South Africa
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. Connectivity
1.2.4. Distribution Channel
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. The internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. Connectivity
1.2.4. Distribution Channel
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. The internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Application outlook
2.2.3. Connectivity outlook
2.2.4. Distribution Channel outlook
2.2.5. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Application outlook
2.2.3. Connectivity outlook
2.2.4. Distribution Channel outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. CGM for Non-Insulin-Treated Type 2 Diabetes Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Product Movement Analysis
4.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Product Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.5. Sensor
4.5.1. Sensor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Applicator
4.6.1. Applicator Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Transmitter
4.7.1. Transmitter Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Device / Reader
4.8.1. Device / Reader Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Product Movement Analysis
4.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Product Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.5. Sensor
4.5.1. Sensor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Applicator
4.6.1. Applicator Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Transmitter
4.7.1. Transmitter Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Device / Reader
4.8.1. Device / Reader Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Application Movement Analysis
5.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Application Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Glucose / Diabetes Management
5.5.1. Glucose / Diabetes Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Lifestyle Monitoring
5.6.1. Lifestyle Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Diet & Nutrition Monitoring
5.7.1. Diet & Nutrition Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Physical Activity & Fitness Monitoring
5.8.1. Physical Activity & Fitness Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Weight Management
5.9.1. Weight Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Application Movement Analysis
5.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Application Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Glucose / Diabetes Management
5.5.1. Glucose / Diabetes Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Lifestyle Monitoring
5.6.1. Lifestyle Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Diet & Nutrition Monitoring
5.7.1. Diet & Nutrition Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Physical Activity & Fitness Monitoring
5.8.1. Physical Activity & Fitness Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Weight Management
5.9.1. Weight Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Connectivity Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Connectivity Movement Analysis
6.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Connectivity Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.5. Bluetooth
6.5.1. Bluetooth Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. 4G / Cellular
6.6.1. 4G / Cellular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. NFC
6.7.1. NFC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Connectivity Movement Analysis
6.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Connectivity Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.5. Bluetooth
6.5.1. Bluetooth Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. 4G / Cellular
6.6.1. 4G / Cellular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. NFC
6.7.1. NFC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Distribution Channel Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Distribution Channel Movement Analysis
7.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Distribution Channel Outlook (USD Million)
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
7.5. Pharmacies
7.5.1. Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. E-commerce
7.6.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Others
7.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Distribution Channel Movement Analysis
7.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Distribution Channel Outlook (USD Million)
7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
7.5. Pharmacies
7.5.1. Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. E-commerce
7.6.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Others
7.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Regional Estimates & Trend Analysis
8.1. Regional Dashboard
8.2. Regional CGM for Non-Insulin-Treated Type 2 Diabetes Market Movement Analysis
8.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Regional Estimates & Trend Analysis by Product & Source
8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
8.5. North America
8.5.1. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. U.S.
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement scenario
8.5.2.5. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. Canada
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement scenario
8.5.3.5. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. Reimbursement scenario
8.5.4.5. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Europe
8.5.6. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.7. UK
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. Reimbursement scenario
8.5.7.5. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.8. Germany
8.5.8.1. Key Country Dynamics
8.5.8.2. Competitive Scenario
8.5.8.3. Regulatory Framework
8.5.8.4. Reimbursement scenario
8.5.8.5. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.9. France
8.5.9.1. Key Country Dynamics
8.5.9.2. Competitive Scenario
8.5.9.3. Regulatory Framework
8.5.9.4. Reimbursement scenario
8.5.9.5. France CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.10. Italy
8.5.10.1. Key Country Dynamics
8.5.10.2. Competitive Scenario
8.5.10.3. Regulatory Framework
8.5.10.4. Reimbursement scenario
8.5.10.5. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.11. Spain
8.5.11.1. Key Country Dynamics
8.5.11.2. Competitive Scenario
8.5.11.3. Regulatory Framework
8.5.11.4. Reimbursement scenario
8.5.11.5. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.12. Russia
8.5.12.1. Key Country Dynamics
8.5.12.2. Competitive Scenario
8.5.12.3. Regulatory Framework
8.5.12.4. Reimbursement scenario
8.5.12.5. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.13. Denmark
8.5.13.1. Key Country Dynamics
8.5.13.2. Competitive Scenario
8.5.13.3. Regulatory Framework
8.5.13.4. Reimbursement scenario
8.5.13.5. Denmark CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.14. Sweden
8.5.14.1. Key Country Dynamics
8.5.14.2. Competitive Scenario
8.5.14.3. Regulatory Framework
8.5.14.4. Reimbursement scenario
8.5.14.5. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.15. Norway
8.5.15.1. Key Country Dynamics
8.5.15.2. Competitive Scenario
8.5.15.3. Regulatory Framework
8.5.15.4. Reimbursement scenario
8.5.15.5. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement scenario
8.6.2.5. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement scenario
8.6.3.5. China CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement scenario
8.6.4.5. India CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement scenario
8.6.5.5. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Framework
8.6.6.4. Reimbursement scenario
8.6.6.5. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Competitive Scenario
8.6.7.3. Regulatory Framework
8.6.7.4. Reimbursement scenario
8.6.7.5. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.8. Singapore
8.6.8.1. Key Country Dynamics
8.6.8.2. Competitive Scenario
8.6.8.3. Regulatory Framework
8.6.8.4. Reimbursement scenario
8.6.8.5. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.9. Malaysia
8.6.9.1. Key Country Dynamics
8.6.9.2. Competitive Scenario
8.6.9.3. Regulatory Framework
8.6.9.4. Reimbursement scenario
8.6.9.5. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.10. Taiwan
8.6.10.1. Key Country Dynamics
8.6.10.2. Competitive Scenario
8.6.10.3. Regulatory Framework
8.6.10.4. Reimbursement scenario
8.6.10.5. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.11. Vietnam
8.6.11.1. Key Country Dynamics
8.6.11.2. Competitive Scenario
8.6.11.3. Regulatory Framework
8.6.11.4. Reimbursement scenario
8.6.11.5. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.12. Philippines
8.6.12.1. Key Country Dynamics
8.6.12.2. Competitive Scenario
8.6.12.3. Regulatory Framework
8.6.12.4. Reimbursement scenario
8.6.12.5. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. Reimbursement scenario
8.7.2.5. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Reimbursement scenario
8.7.3.5. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East & Africa
8.8.1. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Competitive Scenario
8.8.2.3. Regulatory Framework
8.8.2.4. Reimbursement scenario
8.8.2.5. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Competitive Scenario
8.8.3.3. Regulatory Framework
8.8.3.4. Reimbursement scenario
8.8.3.5. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Competitive Scenario
8.8.4.3. Regulatory Framework
8.8.4.4. Reimbursement scenario
8.8.4.5. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Competitive Scenario
8.8.5.3. Regulatory Framework
8.8.5.4. Reimbursement scenario
8.8.5.5. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.2. Regional CGM for Non-Insulin-Treated Type 2 Diabetes Market Movement Analysis
8.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Regional Estimates & Trend Analysis by Product & Source
8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
8.5. North America
8.5.1. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. U.S.
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement scenario
8.5.2.5. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. Canada
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement scenario
8.5.3.5. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. Reimbursement scenario
8.5.4.5. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Europe
8.5.6. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.7. UK
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. Reimbursement scenario
8.5.7.5. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.8. Germany
8.5.8.1. Key Country Dynamics
8.5.8.2. Competitive Scenario
8.5.8.3. Regulatory Framework
8.5.8.4. Reimbursement scenario
8.5.8.5. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.9. France
8.5.9.1. Key Country Dynamics
8.5.9.2. Competitive Scenario
8.5.9.3. Regulatory Framework
8.5.9.4. Reimbursement scenario
8.5.9.5. France CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.10. Italy
8.5.10.1. Key Country Dynamics
8.5.10.2. Competitive Scenario
8.5.10.3. Regulatory Framework
8.5.10.4. Reimbursement scenario
8.5.10.5. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.11. Spain
8.5.11.1. Key Country Dynamics
8.5.11.2. Competitive Scenario
8.5.11.3. Regulatory Framework
8.5.11.4. Reimbursement scenario
8.5.11.5. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.12. Russia
8.5.12.1. Key Country Dynamics
8.5.12.2. Competitive Scenario
8.5.12.3. Regulatory Framework
8.5.12.4. Reimbursement scenario
8.5.12.5. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.13. Denmark
8.5.13.1. Key Country Dynamics
8.5.13.2. Competitive Scenario
8.5.13.3. Regulatory Framework
8.5.13.4. Reimbursement scenario
8.5.13.5. Denmark CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.14. Sweden
8.5.14.1. Key Country Dynamics
8.5.14.2. Competitive Scenario
8.5.14.3. Regulatory Framework
8.5.14.4. Reimbursement scenario
8.5.14.5. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.15. Norway
8.5.15.1. Key Country Dynamics
8.5.15.2. Competitive Scenario
8.5.15.3. Regulatory Framework
8.5.15.4. Reimbursement scenario
8.5.15.5. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement scenario
8.6.2.5. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement scenario
8.6.3.5. China CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement scenario
8.6.4.5. India CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement scenario
8.6.5.5. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Framework
8.6.6.4. Reimbursement scenario
8.6.6.5. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Competitive Scenario
8.6.7.3. Regulatory Framework
8.6.7.4. Reimbursement scenario
8.6.7.5. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.8. Singapore
8.6.8.1. Key Country Dynamics
8.6.8.2. Competitive Scenario
8.6.8.3. Regulatory Framework
8.6.8.4. Reimbursement scenario
8.6.8.5. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.9. Malaysia
8.6.9.1. Key Country Dynamics
8.6.9.2. Competitive Scenario
8.6.9.3. Regulatory Framework
8.6.9.4. Reimbursement scenario
8.6.9.5. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.10. Taiwan
8.6.10.1. Key Country Dynamics
8.6.10.2. Competitive Scenario
8.6.10.3. Regulatory Framework
8.6.10.4. Reimbursement scenario
8.6.10.5. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.11. Vietnam
8.6.11.1. Key Country Dynamics
8.6.11.2. Competitive Scenario
8.6.11.3. Regulatory Framework
8.6.11.4. Reimbursement scenario
8.6.11.5. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.12. Philippines
8.6.12.1. Key Country Dynamics
8.6.12.2. Competitive Scenario
8.6.12.3. Regulatory Framework
8.6.12.4. Reimbursement scenario
8.6.12.5. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. Reimbursement scenario
8.7.2.5. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Reimbursement scenario
8.7.3.5. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East & Africa
8.8.1. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Competitive Scenario
8.8.2.3. Regulatory Framework
8.8.2.4. Reimbursement scenario
8.8.2.5. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Competitive Scenario
8.8.3.3. Regulatory Framework
8.8.3.4. Reimbursement scenario
8.8.3.5. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Competitive Scenario
8.8.4.3. Regulatory Framework
8.8.4.4. Reimbursement scenario
8.8.4.5. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Competitive Scenario
8.8.5.3. Regulatory Framework
8.8.5.4. Reimbursement scenario
8.8.5.5. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.2. Key Company Profiles
9.2.1. Dexcom
9.2.1.1. Company Overview
9.2.1.2. Financial Performance
9.2.1.3. Product Benchmarking
9.2.1.4. Strategic Initiatives
9.2.2. Abbott Laboratories
9.2.2.1. Company Overview
9.2.2.2. Financial Performance
9.2.2.3. Product Benchmarking
9.2.2.4. Strategic Initiatives
9.2.3. Medtronic plc
9.2.3.1. Company Overview
9.2.3.2. Financial Performance
9.2.3.3. Product Benchmarking
9.2.3.4. Strategic Initiatives
9.2.4. Sinocare, Inc. (iCan CGM)
9.2.4.1. Company Overview
9.2.4.2. Financial Performance
9.2.4.3. Product Benchmarking
9.2.4.4. Strategic Initiatives
9.2.5. GlucoRx Limited (AiDEX, Vixxa)
9.2.5.1. Company Overview
9.2.5.2. Financial Performance
9.2.5.3. Product Benchmarking
9.2.5.4. Strategic Initiatives
9.2.6. Bionime (RIGHTEST iFree CGM)
9.2.6.1. Company Overview
9.2.6.2. Financial Performance
9.2.6.3. Product Benchmarking
9.2.6.4. Strategic Initiatives
9.2.7. Nemaura
9.2.7.1. Company Overview
9.2.7.2. Financial Performance
9.2.7.3. Product Benchmarking
9.2.7.4. Strategic Initiatives
9.2.8. i-SENS, Inc.
9.2.8.1. Company Overview
9.2.8.2. Financial Performance
9.2.8.3. Product Benchmarking
9.2.8.4. Strategic Initiatives
9.2. Key Company Profiles
9.2.1. Dexcom
9.2.1.1. Company Overview
9.2.1.2. Financial Performance
9.2.1.3. Product Benchmarking
9.2.1.4. Strategic Initiatives
9.2.2. Abbott Laboratories
9.2.2.1. Company Overview
9.2.2.2. Financial Performance
9.2.2.3. Product Benchmarking
9.2.2.4. Strategic Initiatives
9.2.3. Medtronic plc
9.2.3.1. Company Overview
9.2.3.2. Financial Performance
9.2.3.3. Product Benchmarking
9.2.3.4. Strategic Initiatives
9.2.4. Sinocare, Inc. (iCan CGM)
9.2.4.1. Company Overview
9.2.4.2. Financial Performance
9.2.4.3. Product Benchmarking
9.2.4.4. Strategic Initiatives
9.2.5. GlucoRx Limited (AiDEX, Vixxa)
9.2.5.1. Company Overview
9.2.5.2. Financial Performance
9.2.5.3. Product Benchmarking
9.2.5.4. Strategic Initiatives
9.2.6. Bionime (RIGHTEST iFree CGM)
9.2.6.1. Company Overview
9.2.6.2. Financial Performance
9.2.6.3. Product Benchmarking
9.2.6.4. Strategic Initiatives
9.2.7. Nemaura
9.2.7.1. Company Overview
9.2.7.2. Financial Performance
9.2.7.3. Product Benchmarking
9.2.7.4. Strategic Initiatives
9.2.8. i-SENS, Inc.
9.2.8.1. Company Overview
9.2.8.2. Financial Performance
9.2.8.3. Product Benchmarking
9.2.8.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 4. Global CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 5. Global CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectvity, 2021-2033, (USD Million)
Table 6. Global CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 7. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Country, 2021-2033, (USD Million)
Table 8. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 9. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 10. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 11. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 12. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 13. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 14. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 15. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 16. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 17. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 18. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 19. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 20. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 21. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 22. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 23. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 24. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market, Country, 2021-2033, (USD Million)
Table 25. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 26. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 27. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 28. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 29. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 30. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 31. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 32. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 33. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 34. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 35. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 36. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 37. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 38. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 39. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 40. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 41. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 42. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 43. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 44. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 45. France CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 46. France CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 47. France CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 48. France CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 49. Dernmark CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 50. Dernmark CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 51. Dernmark CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 52. Dernmark CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 53. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 54. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 55. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 56. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 57. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 58. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 59. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 60. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 61. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 62. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 63. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 64. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 65. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market, Country, 2021-2033, (USD Million)
Table 66. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 67. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 68. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 69. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 70. India CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 71. India CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 72. India CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 73. India CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 74. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 75. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 76. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 77. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 78. China CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 79. China CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 80. China CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 81. China CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 82. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 83. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 84. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 85. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 86. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 87. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 88. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 89. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 90. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 91. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 92. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 93. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 94. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 95. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 96. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 97. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 98. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 99. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 100. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 101. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 102. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 103. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 104. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 105. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 106. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 107. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 108. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 109. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 110. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 111. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 112. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 113. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 114. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Country, 2021-2033, (USD Million)
Table 115. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 116. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 117. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 118. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 119. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 120. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 121. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 122. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 123. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 124. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 125. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 126. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 127. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Country, 2021-2033, (USD Million)
Table 128. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 129. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 130. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 131. Middle East & Africa America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 132. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 133. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 134. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 135. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 136. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 137. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 138. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 139. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 140. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 141. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 142. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 143. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 144. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 145. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 146. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 147. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 2. List of abbreviations
Table 3. Global CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 4. Global CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 5. Global CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectvity, 2021-2033, (USD Million)
Table 6. Global CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 7. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Country, 2021-2033, (USD Million)
Table 8. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 9. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 10. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 11. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 12. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 13. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 14. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 15. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 16. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 17. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 18. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 19. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 20. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 21. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 22. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 23. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 24. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market, Country, 2021-2033, (USD Million)
Table 25. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 26. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 27. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 28. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 29. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 30. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 31. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 32. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 33. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 34. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 35. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 36. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 37. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 38. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 39. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 40. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 41. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 42. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 43. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 44. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 45. France CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 46. France CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 47. France CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 48. France CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 49. Dernmark CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 50. Dernmark CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 51. Dernmark CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 52. Dernmark CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 53. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 54. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 55. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 56. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 57. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 58. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 59. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 60. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 61. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 62. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 63. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 64. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 65. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market, Country, 2021-2033, (USD Million)
Table 66. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 67. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 68. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 69. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 70. India CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 71. India CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 72. India CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 73. India CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 74. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 75. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 76. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 77. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 78. China CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 79. China CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 80. China CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 81. China CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 82. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 83. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 84. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 85. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 86. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 87. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 88. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 89. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 90. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 91. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 92. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 93. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 94. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 95. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 96. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 97. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 98. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 99. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 100. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 101. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 102. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 103. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 104. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 105. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 106. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 107. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 108. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 109. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 110. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 111. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 112. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 113. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 114. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Country, 2021-2033, (USD Million)
Table 115. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 116. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 117. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 118. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 119. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 120. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 121. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 122. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 123. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 124. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 125. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 126. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 127. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Country, 2021-2033, (USD Million)
Table 128. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 129. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 130. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 131. Middle East & Africa America CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 132. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 133. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 134. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 135. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 136. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 137. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 138. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 139. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 140. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 141. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 142. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 143. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
Table 144. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market, Product, 2021-2033, (USD Million)
Table 145. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market, Application, 2021-2033, (USD Million)
Table 146. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market, Connectivity, 2021-2033, (USD Million)
Table 147. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market, Distribution Channel, 2021-2033, (USD Million)
List of Figures
Fig 1. Information procurement
Fig 2. Primary research pattern
Fig 3. Market research approaches
Fig 4. Value chain-based sizing & forecasting
Fig 5. Market formulation & validation
Fig 6. CGM for Non-Insulin-Treated Type 2 Diabetes market segmentation
Fig 7. Market driver analysis (Current & future impact)
Fig 8. Market restraint analysis (Current & future impact)
Fig 9. SWOT Analysis, Factor (Political & Legal, Economic and Technological)
Fig 10. Porter’s Five Forces Analysis
Fig 11. CGM for Non-Insulin-Treated Type 2 Diabetes market, product outlook key takeaways (USD Million)
Fig 12. CGM for Non-Insulin-Treated Type 2 Diabetes market: product movement analysis (USD Million), 2025 & 2033
Fig 13. Sensor market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 14. Applicator market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 15. Transmitter market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 16. Device/ Reader market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 17. CGM for Non-Insulin-Treated Type 2 Diabetes market, application outlook key takeaways (USD Million)
Fig 18. CGM for Non-Insulin-Treated Type 2 Diabetes market: application movement analysis (USD Million), 2025 & 2033
Fig 19. Glucose / Diabetes Management market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 20. Lifestyle Monitoring market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 21. Diet & Nutrition Monitoring market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 22. Physical Activity & Fitness Monitoring market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 23. Weight Management market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 24. CGM for Non-Insulin-Treated Type 2 Diabetes market, connectivity outlook key takeaways (USD Million)
Fig 25. CGM for Non-Insulin-Treated Type 2 Diabetes market: connectivity movement analysis (USD Million), 2025 & 2033
Fig 26. Bluetooth market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 27. 4G / Cellular market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 28. NFC market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 29. CGM for Non-Insulin-Treated Type 2 Diabetes market, distribution channel outlook key takeaways (USD Million)
Fig 30. CGM for Non-Insulin-Treated Type 2 Diabetes market: distribution channel movement analysis (USD Million), 2025 & 2033
Fig 31. Pharmacies market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 32. E-commerce market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 33. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 34. CGM for Non-Insulin-Treated Type 2 Diabetes market, regional key takeaways (USD Million)
Fig 35. CGM for Non-Insulin-Treated Type 2 Diabetes market regional outlook, 2025 & 2033, USD Million
Fig 36. North America CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 37. U.S. CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 38. Canada CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 39. Mexico CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 40. Europe CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 41. UK CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 42. Germany CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 43. France CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 44. Italy CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 45. Spain CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 46. Russia CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 47. Denmark CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 48. Sweden CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 49. Norway CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 50. Asia Paciifc CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 51. Japan CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 52. China CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 53. India CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 54. Australia CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 55. South Korea CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 56. Thailand CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 57. Singapore CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 58. Malaysia CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 59. Taiwan CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 60. Vietnam CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 61. Philippines CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 62. Latin America CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 63. Brazil CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 64. Argentina CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 65. Middle East & Africa CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 66. South Africa CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 67. Saudi Arabia CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 68. UAE CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 69. Kuwait CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 70. List of key emerging company’s/indication disruptors/innovators
Fig 2. Primary research pattern
Fig 3. Market research approaches
Fig 4. Value chain-based sizing & forecasting
Fig 5. Market formulation & validation
Fig 6. CGM for Non-Insulin-Treated Type 2 Diabetes market segmentation
Fig 7. Market driver analysis (Current & future impact)
Fig 8. Market restraint analysis (Current & future impact)
Fig 9. SWOT Analysis, Factor (Political & Legal, Economic and Technological)
Fig 10. Porter’s Five Forces Analysis
Fig 11. CGM for Non-Insulin-Treated Type 2 Diabetes market, product outlook key takeaways (USD Million)
Fig 12. CGM for Non-Insulin-Treated Type 2 Diabetes market: product movement analysis (USD Million), 2025 & 2033
Fig 13. Sensor market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 14. Applicator market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 15. Transmitter market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 16. Device/ Reader market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 17. CGM for Non-Insulin-Treated Type 2 Diabetes market, application outlook key takeaways (USD Million)
Fig 18. CGM for Non-Insulin-Treated Type 2 Diabetes market: application movement analysis (USD Million), 2025 & 2033
Fig 19. Glucose / Diabetes Management market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 20. Lifestyle Monitoring market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 21. Diet & Nutrition Monitoring market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 22. Physical Activity & Fitness Monitoring market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 23. Weight Management market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 24. CGM for Non-Insulin-Treated Type 2 Diabetes market, connectivity outlook key takeaways (USD Million)
Fig 25. CGM for Non-Insulin-Treated Type 2 Diabetes market: connectivity movement analysis (USD Million), 2025 & 2033
Fig 26. Bluetooth market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 27. 4G / Cellular market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 28. NFC market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 29. CGM for Non-Insulin-Treated Type 2 Diabetes market, distribution channel outlook key takeaways (USD Million)
Fig 30. CGM for Non-Insulin-Treated Type 2 Diabetes market: distribution channel movement analysis (USD Million), 2025 & 2033
Fig 31. Pharmacies market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 32. E-commerce market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 33. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig 34. CGM for Non-Insulin-Treated Type 2 Diabetes market, regional key takeaways (USD Million)
Fig 35. CGM for Non-Insulin-Treated Type 2 Diabetes market regional outlook, 2025 & 2033, USD Million
Fig 36. North America CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 37. U.S. CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 38. Canada CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 39. Mexico CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 40. Europe CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 41. UK CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 42. Germany CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 43. France CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 44. Italy CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 45. Spain CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 46. Russia CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 47. Denmark CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 48. Sweden CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 49. Norway CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 50. Asia Paciifc CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 51. Japan CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 52. China CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 53. India CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 54. Australia CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 55. South Korea CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 56. Thailand CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 57. Singapore CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 58. Malaysia CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 59. Taiwan CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 60. Vietnam CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 61. Philippines CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 62. Latin America CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 63. Brazil CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 64. Argentina CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 65. Middle East & Africa CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 66. South Africa CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 67. Saudi Arabia CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 68. UAE CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 69. Kuwait CGM for non-insulin-treated Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig 70. List of key emerging company’s/indication disruptors/innovators
Companies Mentioned
- Dexcom
- Abbott Laboratories
- Medtronic plc
- Sinocare, Inc. (iCan CGM)
- GlucoRx Limited (AiDEX, Vixxa)
- Bionime (RIGHTEST iFree CGM)
- Nemaura
- i-SENS, Inc.
